News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

89bio, Inc. (NASDAQ: ETNB) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.

89bio to Participate in the Leerink Partners Global Healthcare Conference

89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock, down previously from $29.00.

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates [Yahoo! Finance]

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

5/9/2024

04:05 pm

etnb

-4.4%

MISS

Form SCHEDULE 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Form S-8 89bio, Inc.

Form 10-K 89bio, Inc. For: Dec 31

Form 8-K 89bio, Inc. For: Feb 27

Form 4 89bio, Inc. For: Feb 17 Filed by: Martins Ryan

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}